Tweet
Posted July 20, 2022.
doi: https://doi.org/10.1101/2022.07.19.500484
Gaelle Frenois-Veyrat, Franck Gallardo, Olivier Gorge, Elie Marcheteau, Olivier Ferraris, Artem Baidaliuk, Anne-Laure Favier, Cecile Enfroy, Xavier Holy, Jeremy Lourenco, Rhea Khoury, Flora Nolent, Douglas W. Grosenbach, Dennis Hruby, Audrey Ferrier, Frederic Iseni, View ORCID ProfileEtienne Simon-Loriere, Jean-Nicolas Tournier
Abstract
The ongoing monkeypox virus (MPXV) outbreak is the largest ever recorded outside of Africa. Genomic analysis revealed a divergent phylogenetic lineage within clade 3, and atypical clinical presentations have been noted. We report the sequencing and isolation of the virus from the first clinical case diagnosed in France in May 2022. We tested the in vitro effect of tecovirimat (ST-246), a FDA approved drug, against this novel strain, showing efficacy at the nanomolar range. In comparison, cidofovir showed activity at micromolar concentrations. These results and the safety profile of tecovirimat strongly support its use in clinical care of severe forms for the 2022 MPXV outbreak.
doi: https://doi.org/10.1101/2022.07.19.500484
Gaelle Frenois-Veyrat, Franck Gallardo, Olivier Gorge, Elie Marcheteau, Olivier Ferraris, Artem Baidaliuk, Anne-Laure Favier, Cecile Enfroy, Xavier Holy, Jeremy Lourenco, Rhea Khoury, Flora Nolent, Douglas W. Grosenbach, Dennis Hruby, Audrey Ferrier, Frederic Iseni, View ORCID ProfileEtienne Simon-Loriere, Jean-Nicolas Tournier
Abstract
The ongoing monkeypox virus (MPXV) outbreak is the largest ever recorded outside of Africa. Genomic analysis revealed a divergent phylogenetic lineage within clade 3, and atypical clinical presentations have been noted. We report the sequencing and isolation of the virus from the first clinical case diagnosed in France in May 2022. We tested the in vitro effect of tecovirimat (ST-246), a FDA approved drug, against this novel strain, showing efficacy at the nanomolar range. In comparison, cidofovir showed activity at micromolar concentrations. These results and the safety profile of tecovirimat strongly support its use in clinical care of severe forms for the 2022 MPXV outbreak.
Comment